Market Cap 124.53M
Revenue (ttm) 602.46M
Net Income (ttm) 2.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.35%
Debt to Equity Ratio 0.00
Volume 113,000
Avg Vol 228,200
Day's Range N/A - N/A
Shares Out 10.99M
Stochastic %K 6%
Beta 0.48
Analysts Hold
Price Target $15.00

Company Profile

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. It also provides bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding,...

Industry: Personal Services
Sector: Consumer Cyclical
Phone: 410 581 8042
Address:
100 International Drive, 18th Floor, Baltimore, United States
ZacksResearch
ZacksResearch Dec. 24 at 7:24 PM
$MED struggles with a 36.2% revenue drop — is recovery in sight? 📉 👥 Coach base shrinks by 35%, impacting sales 🛠️ Rightsizing actions in place to stabilize margins 📈 Expected inflection point in Q4 of fiscal 2025 as initiatives kick in Discover the full story here 👉 https://www.zacks.com/stock/news/2808820/medifasts-third-quarter-revenue-fell-36-is-stabilization-near?cid=sm-stocktwits-2-2808820-body-26325&ADID=SYND_STOCKTWITS_TWEET_2_2808820_BODY_26325
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:24 PM
$MED just saw Q3 revenue drop 36% — but is the bottom finally forming? ⚠️ Medifast’s revenue plunged as its coach base shrank, yet restructuring and productivity initiatives are aimed at stabilizing results by late 2025. The setup is ugly, but the turnaround angle is clearly being framed. See whether stabilization is realistic 👉 https://www.zacks.com/stock/news/2808820/medifasts-third-quarter-revenue-fell-36-is-stabilization-near?cid=sm-stocktwits-2-2808820-teaser-26295&ADID=SYND_STOCKTWITS_TWEET_2_2808820_TEASER_26295
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 23 at 9:32 PM
$MED Share Price: $11.15 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $1.57 – $1.94 Target Zone: $2.75 – $3.36 Potential Upside: 65% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 5:26 PM
GLP-1 pressure is real — can $MED fight back? ⚠️💪 MED is leaning into long-term metabolic health, pushing programs designed to preserve muscle and support lasting wellness as GLP-1 adoption grows. Can this growth strategy hold up against the GLP-1 wave? Find out here 👉 https://www.zacks.com/stock/news/2806338/can-medifast-overcome-glp-1-pressure-with-its-growth-strategy?cid=sm-stocktwits-2-2806338-teaser-25452&ADID=SYND_STOCKTWITS_TWEET_2_2806338_TEASER_25452
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 4:26 PM
$MED down 14.1% in 6 months — is it time to pivot to growth? 📉 Medifast is focusing on metabolic health and digital tools to address evolving weight-loss dynamics, yet it carries a Zacks Rank #4 (Sell). Meanwhile, $COCO boasts Zacks Rank #1, with impressive growth and earnings surprises, and $MNST sports a Zacks Rank #1. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2806338/can-medifast-overcome-glp-1-pressure-with-its-growth-strategy?cid=sm-stocktwits-2-2806338-body-25453&ADID=SYND_STOCKTWITS_TWEET_2_2806338_BODY_25453
0 · Reply
Mr__G
Mr__G Dec. 13 at 1:15 PM
$MED they have 173mil in Cash and short term investment 🤣
0 · Reply
Jumpy58
Jumpy58 Dec. 10 at 6:58 PM
$MED I think this stock has a future. In my opinion, the worst is over and I'm confident in a slow turnaround. My sentiment is improving. I'm confident
0 · Reply
justcomments
justcomments Dec. 9 at 2:59 PM
$MED bouncing? Unheard of.
0 · Reply
Mr__G
Mr__G Dec. 5 at 4:07 PM
$MED just buyback some shares, bring back good momentum, that helps the whole company
0 · Reply
bginvest
bginvest Dec. 4 at 8:40 PM
$MED $OTLY if i should put money in this sector health food ( waiting ) I would recommend OTLY at this point but I am personally only watching right now MED is shrinking as a company for longer period without profit there probably is continuing OTLY is growing but are expensive compared with other growth companies But if I should choose one it would be OTLY anytime I am staying on the sideline and hoping for a investment in OTLY when it’s closer to be profitable and if there still is growth they could’ve a bright future but still need money growth Best of luck 😘🤞🏦
1 · Reply
Latest News on MED
Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 6:36 PM EST - 7 weeks ago

Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript


Medifast Announces Third Quarter 2025 Financial Results

Nov 3, 2025, 4:05 PM EST - 7 weeks ago

Medifast Announces Third Quarter 2025 Financial Results


Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:56 PM EDT - 5 months ago

Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript


Medifast Announces Second Quarter 2025 Financial Results

Aug 4, 2025, 4:05 PM EDT - 5 months ago

Medifast Announces Second Quarter 2025 Financial Results

LFMD


Medifast: Coach Surge Fuels Growth

Jul 3, 2025, 2:48 AM EDT - 6 months ago

Medifast: Coach Surge Fuels Growth


Medifast, Inc. (MED) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 6:03 PM EDT - 8 months ago

Medifast, Inc. (MED) Q1 2025 Earnings Call Transcript


Medifast Announces First Quarter 2025 Financial Results

Apr 28, 2025, 4:05 PM EDT - 8 months ago

Medifast Announces First Quarter 2025 Financial Results

LFMD


Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect

Mar 28, 2025, 9:21 AM EDT - 9 months ago

Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect


Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 7:06 PM EST - 11 months ago

Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript


Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 5:56 PM EST - 1 year ago

Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript


Medifast Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

Medifast Announces Third Quarter 2024 Financial Results


ZacksResearch
ZacksResearch Dec. 24 at 7:24 PM
$MED struggles with a 36.2% revenue drop — is recovery in sight? 📉 👥 Coach base shrinks by 35%, impacting sales 🛠️ Rightsizing actions in place to stabilize margins 📈 Expected inflection point in Q4 of fiscal 2025 as initiatives kick in Discover the full story here 👉 https://www.zacks.com/stock/news/2808820/medifasts-third-quarter-revenue-fell-36-is-stabilization-near?cid=sm-stocktwits-2-2808820-body-26325&ADID=SYND_STOCKTWITS_TWEET_2_2808820_BODY_26325
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:24 PM
$MED just saw Q3 revenue drop 36% — but is the bottom finally forming? ⚠️ Medifast’s revenue plunged as its coach base shrank, yet restructuring and productivity initiatives are aimed at stabilizing results by late 2025. The setup is ugly, but the turnaround angle is clearly being framed. See whether stabilization is realistic 👉 https://www.zacks.com/stock/news/2808820/medifasts-third-quarter-revenue-fell-36-is-stabilization-near?cid=sm-stocktwits-2-2808820-teaser-26295&ADID=SYND_STOCKTWITS_TWEET_2_2808820_TEASER_26295
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 23 at 9:32 PM
$MED Share Price: $11.15 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $1.57 – $1.94 Target Zone: $2.75 – $3.36 Potential Upside: 65% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 5:26 PM
GLP-1 pressure is real — can $MED fight back? ⚠️💪 MED is leaning into long-term metabolic health, pushing programs designed to preserve muscle and support lasting wellness as GLP-1 adoption grows. Can this growth strategy hold up against the GLP-1 wave? Find out here 👉 https://www.zacks.com/stock/news/2806338/can-medifast-overcome-glp-1-pressure-with-its-growth-strategy?cid=sm-stocktwits-2-2806338-teaser-25452&ADID=SYND_STOCKTWITS_TWEET_2_2806338_TEASER_25452
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 4:26 PM
$MED down 14.1% in 6 months — is it time to pivot to growth? 📉 Medifast is focusing on metabolic health and digital tools to address evolving weight-loss dynamics, yet it carries a Zacks Rank #4 (Sell). Meanwhile, $COCO boasts Zacks Rank #1, with impressive growth and earnings surprises, and $MNST sports a Zacks Rank #1. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2806338/can-medifast-overcome-glp-1-pressure-with-its-growth-strategy?cid=sm-stocktwits-2-2806338-body-25453&ADID=SYND_STOCKTWITS_TWEET_2_2806338_BODY_25453
0 · Reply
Mr__G
Mr__G Dec. 13 at 1:15 PM
$MED they have 173mil in Cash and short term investment 🤣
0 · Reply
Jumpy58
Jumpy58 Dec. 10 at 6:58 PM
$MED I think this stock has a future. In my opinion, the worst is over and I'm confident in a slow turnaround. My sentiment is improving. I'm confident
0 · Reply
justcomments
justcomments Dec. 9 at 2:59 PM
$MED bouncing? Unheard of.
0 · Reply
Mr__G
Mr__G Dec. 5 at 4:07 PM
$MED just buyback some shares, bring back good momentum, that helps the whole company
0 · Reply
bginvest
bginvest Dec. 4 at 8:40 PM
$MED $OTLY if i should put money in this sector health food ( waiting ) I would recommend OTLY at this point but I am personally only watching right now MED is shrinking as a company for longer period without profit there probably is continuing OTLY is growing but are expensive compared with other growth companies But if I should choose one it would be OTLY anytime I am staying on the sideline and hoping for a investment in OTLY when it’s closer to be profitable and if there still is growth they could’ve a bright future but still need money growth Best of luck 😘🤞🏦
1 · Reply
Investor6
Investor6 Dec. 3 at 5:33 PM
Cheap rofitable stocks with also negative Enterprise Value. $TRVG GTEC $MED TRVG: unloved by the vast majority of the analysts, they see squeezed margins, no growth for the near future. Are they right? GTEC: A microcap with improved results, but without recent news, in a market where such small stocks are invisible, for now at least. MED: Revenues dropped, analysts are cautious, but the management believes things will improve in 2026 with new business segments.
0 · Reply
Estimize
Estimize Nov. 26 at 9:00 PM
Wall St is expecting -0.82 EPS for $MED Q4 [Reporting 02/24 AMC] http://www.estimize.com/intro/med?chart=historical&metric_name=eps&utm_con
0 · Reply
FRAGMENTS
FRAGMENTS Nov. 26 at 3:08 AM
1 · Reply
FRAGMENTS
FRAGMENTS Nov. 25 at 1:15 PM
$CNC Deep Value Report Updated — Part 2 on $CNC is live. 🩺📊 From “de-risked” guidance to a $6.7B goodwill hit, we walk through the 2025 ACA / Medicaid shock, HBR math and what mid-cycle EPS really looks like now. If you care about managed care, policy risk and cash flow. HERE: https://cundilldeepvalue.substack.com/p/fragments-deep-value-report-centene $UNH $MED $MPW
0 · Reply
NVDAMillionaire
NVDAMillionaire Nov. 18 at 9:27 AM
$MED Brilliant piece that captures MED's situation perfectly. So if you want to update your understanding of MED or get to know MED better, this is essential reading. https://beyondspx.com/quote/MED/analysis/medifast-s-metabolic-health-revolution-fueling-future-growth-through-coach-led-transformation-nyse-med
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 11 at 1:39 PM
$MED Share Price: $11.80 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $2.03 – $2.50 Target Zone: $3.75 – $4.59 Potential Upside: 75% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
justcomments
justcomments Nov. 5 at 7:08 PM
$MED I noticed a pattern in MED. They say they lost money. Then the cash in bank increases. This quarter they made 10.8M dollars. That's 98 cents per share. That's a lot of money for a small cap like this. They say they had a really bad quarter. The profit margin fell from 70% to 69.5%. Is that right? Did I hear it correctly? That's a disaster, no? What's the next quarter profit margin? 69.3%? Keep shorting.
0 · Reply
justcomments
justcomments Nov. 5 at 6:43 PM
$MED OZEMPIC awareness is slowly spreading. Very slowly. Pancreatitis cancer. Thyroid cancer. Kidney damage. Heart failure. Gastrointestinal paralysis. Eye problems. This is serious. When these people decide to go back to food - it will be interesting for MED.
0 · Reply
_StockFox_
_StockFox_ Nov. 5 at 12:48 AM
$MED added a few shares today $SPY $QQQ
0 · Reply
ZacksResearch
ZacksResearch Nov. 4 at 5:09 PM
$MED feels the pinch from fewer OPTAVIA Coaches, but shifting focus could spark a new phase 🔄💪 Q3 results showed coach declines weighing on performance, yet the company’s pivot toward metabolic health signals a strategic growth move. Full story on the transition here 👉 https://www.zacks.com/stock/news/2784765/medifasts-q3-loss-wider-than-expected-sales-decline-36-yy?cid=sm-stocktwits-2-2784765-teaser-19330&ADID=SYND_STOCKTWITS_TWEET_2_2784765_TEASER_19330
0 · Reply
ZacksResearch
ZacksResearch Nov. 4 at 4:09 PM
$MED misses on EPS — is the shift to metabolic health the right move? 🤔 📉 EPS loss of 21 cents vs. expected 1 cent loss 📊 Revenue of $89.4M beats estimate but drops 36.2% YoY 🚪 Active earning OPTAVIA coaches down 35% amid GLP-1 adoption Full breakdown here 👉 https://www.zacks.com/stock/news/2784765/medifasts-q3-loss-wider-than-expected-sales-decline-36-yy?cid=sm-stocktwits-2-2784765-body-19331&ADID=SYND_STOCKTWITS_TWEET_2_2784765_BODY_19331
0 · Reply
DataJim
DataJim Nov. 4 at 3:48 PM
$MED Have they given any insight into when they will return to profitability? the Q4 projected loss is the biggest one yet.
1 · Reply